Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study

Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study

Introduction: The mainstay systemic treatment for non-oncogenic addictive advanced stage non-small cell lung cancer is chemotherapy. Anti-angiogenic agents are additive compounds that enhance disease control and lead to improvement of overall survival benefit. Recently PD-(L)1 blockage, a checkpoint...

Full description

Saved in:

Bibliographic Details
Main Authors:	Krittiya Korphaisarn, Pongwut Danchaivijitr, Thanyanan Reungwetwattana, Busayamas Chewaskulyong, Luangyot Thongthieang, Jarin Chindaprasirt, Kunlatida Maneenil, Chirawadee Sathitruangsak, Chanida Vinayanuwattikun
Other Authors:	Siriraj Hospital
Format:	Article
Published:	2022
Subjects:	Biochemistry, Genetics and Molecular Biology Medicine
Online Access:	https://repository.li.mahidol.ac.th/handle/123456789/76203
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Mahidol University

Similar Items

A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer
by: Sumitra Thongprasert, et al.
Published: (2018)

COMBINATORIAL TARGETED THERAPY OF MAB AND NINTEDANIB ENHANCES CANCER CELL LETHALITY
by: TEO WAN CHING JOCELYN
Published: (2021)

Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
by: Chaiyut Charoentum, et al.
Published: (2018)

Docetaxel Pharmacogenetics and its Influence on the Pharmacokinetics/Pharmacodynamics of Docetaxel in Asian Nasopharyngeal Cancer Patients
by: CHEW SIN CHI
Published: (2013)

Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202
by: Porntipa Korprasertthaworn, et al.
Published: (2020)

Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
by: Suthinee Ithimakin, et al.
Published: (2020)

Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)
by: Huang, R.Y.-J, et al.
Published: (2020)

Cutaneous reaction associated with weekly docetaxel administration
by: Chew, L., et al.
Published: (2014)

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
by: Piyada Sitthideatphaiboon, et al.
Published: (2022)

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: A multicenter analysis in Thailand
by: Nuttapong Ngamphaiboon, et al.
Published: (2020)

Benefits of prophylactic percutaneous gastrostomy in patients with nasopharyngeal cancer receiving concurrent chemoradiotherapy: A multicenter analysis
by: Tanadech Dechaphunkul, et al.
Published: (2022)

Docetaxel enhances lysosomal function through TFEB activation
by: Zhang J., et al.
Published: (2019)

Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel
by: Sun, B., et al.
Published: (2014)

Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel
by: Sun, B., et al.
Published: (2014)

Management of acquired resistance to ALK inhibitors: Repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
by: Naiyarat Prasongsook, et al.
Published: (2022)

MET exon 14 deletion (METex14): Finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval
by: Thanyanan Reungwetwattana, et al.
Published: (2018)

Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer
by: Goh, B.C., et al.
Published: (2014)

Lung Cancer in Thailand
by: Thanyanan Reungwetwattana, et al.
Published: (2020)

Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
by: Thanyanan Reungwetwattana, et al.
Published: (2022)

Chemotherapy for non-small-cell lung carcinoma: From a blanket approach to individual therapy
by: Thanyanan Reungwetwattana, et al.
Published: (2018)

Real-world evidence of cisplatin versus carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicenter analysis
by: Arunee Dechaphunkul, et al.
Published: (2022)

Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients
by: Sutima Luangdilok, et al.
Published: (2018)

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC)
by: Thanyanan Reungwetwattana, et al.
Published: (2018)

Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
by: Charoentum C., et al.
Published: (2014)

Nanomedicine: Enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation
by: Gan, C.W., et al.
Published: (2014)

A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers
by: Yong, W.-P., et al.
Published: (2014)

Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots
by: Muthu, M.S., et al.
Published: (2014)

Trastuzumab-conjugated vitamin e TPGS liposomes for sustained and targeted delivery of docetaxel
by: Raju, A., et al.
Published: (2014)

Trastuzumab-conjugated vitamin e TPGS liposomes for sustained and targeted delivery of docetaxel
by: Raju, A., et al.
Published: (2014)

Effect of an education program on the prevention of ventilator-associated pneumonia: A multicenter study.
by: Somwang Danchaivijitr, et al.
Published: (2018)

In Vitro and In Vivo Investigation of Nanoparticles of A Novel Copolymer for Substained and Controlled Delivery of Docetaxel
by: GAN CHEE WEE
Published: (2010)

Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer
by: Nao Tagawa, et al.
Published: (2018)

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies
by: Goh, B.-C., et al.
Published: (2014)

Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel
by: Feng, S.-S., et al.
Published: (2014)

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A phase II study in Caucasian and Asian patients
by: Millward, M.J., et al.
Published: (2016)

Association of histologic subtypes with genetic alteration and pd-l1 expression in pulmonary adenocarcinoma
by: Bantita Phruttinarakorn, et al.
Published: (2020)

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
by: Thanyanan Reungwetwattana, et al.
Published: (2018)

In Vitro and In Vivo Study of Vitamin E TPGs Coated Immunoliposomes for Sustained and Targeted Delivery of Docetaxel
by: ANANDHKUMAR RAJU
Published: (2012)

Cluster Symptoms Reduction via Telephone-Based Intervention in Thai Breast Cancer Patients Undergoing 4-Cycle Adjuvant Chemotherapy: A Randomized-Controlled Trial
by: Piyawadee Ninsen, et al.
Published: (2022)